Ioxilan

Ioxilan
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	intravenously
ATC code	V08AB12 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	N/A
Protein binding	negligible
Elimination half-life	2 hours
Excretion	Mostly renal
Identifiers
	IUPAC name 1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide;
CAS Number	107793-72-6 ;
PubChem CID	3743;
ChemSpider	3612 ;
UNII	A4YJ7J11TG;
KEGG	D02161 ;
ChEMBL	ChEMBL1201075 ;
CompTox Dashboard (EPA)	DTXSID0048717 ;
Chemical and physical data
Formula	C18H24I3N3O8
Molar mass	791.112 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C;
	InChI InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) ; Key:UUMLTINZBQPNGF-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.